TY  - CHAP
M1  - Book, Section
TI  - Phosphodiesterase Inhibitors
A1  - Suyderhoud, Johan P.
A2  - Freeman, Brian S.
A2  - Berger, Jeffrey S.
PY  - 2014
T2  - Anesthesiology Core Review: Part One Basic Exam
AB  - Phosphodiesterase  inhibitors  (PDEI)  are  a  broad  category  of  drugs  that  act  to  prevent  the  hydrolysis  of  cyclic  3,5  adenosine  monophosphate  (cAMP)  and  3,5  guanosine  monophosphate  (cGMP)  by  phosphodiesterases.  Phosphodiesterases  (PDEs)  are  a  heterogeneous  group  of  at  least  11  isoenzymes,  with  over  50  isoforms,  present  in  a  wide  variety  of  tissues,  and  their  actions  are  important  in  regulating  intracellular  levels  of  cAMP  and  cGMP,  both  important  components  of  intracellular  second  messenger  systems.  Inhibition  of  phosphodiesterases  will  lead  to  an  increase  in  intracellular  cyclic  nucleotides  and  amplify  their  actions  in  various  organ  beds.  The  main  clinical  interest  of  anesthesiologists  resides  with  the  direct  effects  of  PDEIs  in  cardiac  and  vascular  tissue  mediated  by  the  PDEI  type  III  (3)  isoenzyme.  Other  PDEIs  have  clinical  applications  in  treating  primary  pulmonary  hypertension,  persistent  pulmonary  hypertension  of  the  newborn,  and  erectile  dysfunction  (PDEI  type  5);  this  will  be  discussed  briefly  at  the  conclusion  of  this  chapter.  PDEI,  primarily  type  4,  may  also  prove  to  be  of  benefit  in  treating  inflammatory  (eg,  reactive  airway  disease)  and  some  neoplastic  disease  states  (where  cAMP  levels  have  found  to  be  reduced).  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/17
UR  - accessanesthesiology.mhmedical.com/content.aspx?aid=1102569702
ER  -